This Newsletter is shared on behalf of ICLAC. If you have any questions or concerns about the content, please send an email to info@immunizelac.org
NEW ICLAC Newsletter!
If you subscribe to our newsletter, please be sure to add info@immunizelac.org to your contact list, as we will be delivering the newsletter directly from our website starting in August 2024. If you haven’t yet subscribed to our newsletter, please visit: https://immunizelac.org/newsletter/
Visit our ICLAC Website to stay updated on upcoming changes and announcements:
- Membership and Sponsorship Program: A new structure to sustain our programs and grow our impact.
- Innovative Events and Forums: Opportunities to collaborate, learn, and innovate through tailored events.
Fall Forum 2025 Registration is Now Open!
The annual ICLAC Fall Vaccine Forum will be held on Thursday, October 30, 2025 at the California Endowment from 10:00am-2:00pm PT.
Please see below registration links for more information:
IN PERSON:
ICLACFallForumInPerson.eventbrite.com
(Space is limited; please register by Thursday, 10/23).
ONLINE:
ICLACFallForumOnline.eventbrite.com
(Registration is open until 10/30).
Want to help? You can support this event and future forums by becoming a member or donating any amount: https://immunizelac.org/donate/
CDC Advisory Committee on Immunization Practices (ACIP) Update
ACIP, the CDC group responsible for reviewing and voting on issues pertinent to US vaccine policy, met on September 18th and 19th. The committee of 12 included five members appointed just days before the meeting began.
On Day 1, the committee reviewed presentations concerning whether the combination measles, mumps, rubella, and varicella (MMR-V) vaccine should continue to be used for the childhood first dose, recommended at age 12-15 months, due to a small increased risk of febrile seizures. The previous recommendation allowed consideration of use in children under 4 with shared decision-making if the family wished to reduce the number of injections. The committee ultimately voted 9-3 that children under age 4 years should receive the MMR vaccine separate from the stand-alone varicella vaccine. After initial confusion among the committee, a follow-up vote similarly restricted Vaccines for Children (VFC) funding to cease coverage for the MMR-V, only funding the MMR vaccine and separate Varicella vaccine in children under 4 years old. This decision limits parental and provider choice and may result in reduced uptake of MMR and/or varicella vaccines by reducing access to an important vaccine option.
Also on Day 1, the topic of shifting the hepatitis B birth dose to no earlier than 1 month of age was also discussed, despite the existence of no new substantive evidence related to safety. In a surprise move, the committee voted to table the issue indefinitely at the beginning of Day 2.
Day 2 of the meeting was primarily focused on COVID-19 vaccines, notably taking place much closer to the Fall respiratory vaccine season compared to past years, which has delayed access, especially in children. In several contentious exchanges, voting members at times attempted to introduce unsupported concerns about risk and made inconsistent statements about the level of evidence necessary to support conclusions about vaccine safety and efficacy. Speakers during the public comment period were universally in support of strong COVID-19 vaccine recommendations. Commenters included ICLAC board member Dr. Richard Dang who highlighted the safety record of the COVID-19 vaccines and the importance of maintaining pharmacy-based access to vaccines without the need for a prescription.
The committee ultimately voted 12-0 that the COVID-19 vaccines should be available for everyone over the age of 6 months with shared decision making. This decision represents a significant weakening of the recommendation. Further, it is likely to contribute to ongoing confusion among providers, sow doubt regarding the safety and value of vaccination among members of the public. It also raises concerns around vaccine access. A subsequent vote as to whether prescriptions should be required for COVID-19 vaccines failed, preserving access to vaccines in pharmacies.
ACIP chair, Dr. Martin Kulldorff again refused to commit to the use of any specific robust and validated method for future work by the committee and its workgroups. To ensure adequate consideration of all pertinent factors including benefits, harms, acceptability, and equity among others, the Evidence to Recommendation (EtR) Framework had been used for decades until it was abandoned prior to the June 2025 meeting.
California Legislative Update
Just ahead of the September ACIP meeting, California Governor Gavin Newsome signed legislation, CA AB 144, which allows California healthcare providers, including pharmacists, to follow vaccine recommendations and guidance from the state Department of Public Health rather than that provided by ACIP and CDC. This important move will protect science-based vaccine programs and the health of California residents.
LA County Vaccine, COVID-19 News, Updates & More
Measles Updates and Resources
As of September 2, 2025, there have been a total of 1,431 confirmed* measles cases reported in the United States. Among these, 1,413 of the measles cases were reported by 42 jurisdictions: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Missouri, Montana, Nebraska, New Jersey, New Mexico, New York City, New York State, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, Wisconsin, and Wyoming. A total of 18 measles cases were reported among international visitors to the U.S.
There have been 35 outbreaks** reported in 2025, and 86% of confirmed cases (1,231 of 1,431) are outbreak-associated. For comparison, 16 outbreaks were reported during 2024 and 69% of cases (198 of 285) were outbreak-associated.
CDC Measles Cases and Outbreaks
MMR Vaccination Guidance Reminders
Before international travel
- All ages: up-to-date measles vaccination
- Ages 6 – 11 months: 1 dose before departure, then routine 2-dose series
- Age 12 months and older: First dose now, 2nd dose 28 days later
Before domestic travel
For people who live in or visit domestic measles outbreak areas, see CDC’s Measles Cases and Outbreaks page for updated MMR vaccination recommendations issued by state or local health departments.
Click Here for LACDPH Measles Information for Public and Providers
RFK Jr and MAHA: dangerous, emboldened, and escalating
From The Lancet, August 23, 2025
The week beginning Aug 4, 2025 was the most dangerous and tragic week of Robert F Kennedy Jr’s tenure yet: a fatal CDC shooting by a gunman distrustful of COVID-19 vaccines, the cancellation of US$500 million in mRNA research funding, and his malicious call to retract a peer-reviewed Annals of Internal Medicine paper on vaccine safety. RFK Jr has built an increasingly powerful movement in Make America Healthy Again (MAHA). Either through incompetence or disinformation, the actions of this movement pose the greatest threat to the health of Americans and millions of people globally.
Kennedy cited lack of effectiveness, mRNA COVID-19 vaccines encouraging mutations in the pandemic, and a 181-page document that led him to conclude that the risks outweighed the benefits in further researching the mRNA vaccine platform. Later that week, Jay Bhattacharya, National Institute of Health Director, argued that the cancellation was because of public mistrust. But even this scientifically illiterate act of self-sabotage did not satisfy some of the MAHA base who dwell in a world inverted, where the familiar words of trust, data, and transparency are systematically used to discredit, dismantle, and undermine scientific institutions and individuals.
First, to the science. Multiple large, robust, and peer-reviewed clinical studies have concluded that millions of lives were saved during the COVID-19 pandemic from mRNA vaccines. Not by stopping transmission, but by preventing severe disease, hospitalisation, and death. There is no evidence that mRNA vaccines increase the virus mutation rate. The 181-page bibliography that Kennedy refers to contains many small, non-peer-reviewed studies and carefully selected paragraphs that do not discuss empirical data or major findings. The mRNA vaccine platform is the most effective tool we have in pandemic preparedness. The rapid and transitory nature of mRNA-encoded proteins that do not need to enter the nucleus or risk genomic integration makes them promising tools for infectious and non-infectious diseases such as cancer. Several areas continue to need refinement including: storability, stability, duration of expression, and targetability. Further research might achieve this. Like any intervention, mRNA vaccines are not perfect. There are known adverse events—a large observational study of 298 792 852 doses of mRNA vaccines given during the first 6 months of the US COVID-19 vaccination programme found the rate of myopericarditis to be 4·4 per million doses, and that most adverse events were mild and short-lived. The public health community must continue to communicate these adverse events transparently and weigh the risks and benefits for each population.
Second, to trust. It is true that trust in public health was damaged during the COVID-19 pandemic and that many US citizens are concerned because of the discordance between the amount the US spends on health care per capita (about $13 000) and the overall poor population health of Americans (the lowest life expectancy of any high-income country). It is understandable that the bold proclamations and blame that Kennedy and MAHA propagate may be seductive. Their movement is based on the premise that big pharma and big food profit from keeping Americans unhealthy. Undoubtedly there are many problems with an under-regulated US food system and a privatised health-care system. But a recent Pew Research Poll on who influences health policy and health priorities indicates that eight out of ten Americans agree that cancer, obesity, heart disease, and opioid addictions are key issues and that seven out of ten feel that health insurance companies are overly influential. Where then are the plans for universal health-care coverage or to regulate health insurance companies? To fund scientific endeavours to face these challenges? To regulate agriculture and the food environment? A second MAHA report is promised but as yet there is no indication that these plans will be proposed. Rather, Kennedy and some leaders of the MAHA movement choose to nurture mistrust through disinformation and misdirect genuine concerns to align with an anti-science and anti-vaccine agenda. Supported by a band of wellness industry entrepreneurs and influencers who sometimes directly profit from these diversions, this is an agenda that will do nothing for trust, science, or for health.
Although the health and science community must engage, and understand what has made this movement so beguiling, nobody should be under any illusions as to what it is—a dangerous pseudoscientific programme of work that supports a corrupt and unscientific wellness industry, seeks to discredit mainstream medicine, and portrays institutions and experts as enemies, not partners
Source: The Lancet, Volume 406, Issue 10505, 779
CDC data reveal kindergarten vaccination coverage declined and exemptions rose in the 2024–25 school year
Updated Recommendations
AAP releases evidence-based immunization schedule; calls on payers to cover recommendations
The AAP has published an independent evidence-based immunization schedule for children and adolescents in the wake of federal officials undermining the rigorous scientific process for making recommendations. ACOG Releases Updated Maternal Immunization Guidance for COVID-19, Influenza, and RSV
On August 22nd, the American College of Obstetricians and Gynecologists (ACOG) released updated clinical guidance regarding vaccination during pregnancy against COVID-19, influenza, and RSV.
August is National Immunization Awareness Month, and the American College of Physicians (ACP) is urging adults to get all recommended immunizations for protection against preventable diseases such as influenza, RSV, pneumonia and COVID-19. CDC Adopts 2025-2026 Influenza Vaccine Recommendations
● ACIP June 2025 ● Reaffirmed the recommendations for routine annual influenza vaccination of persons aged ≥ 6 months ● Recommended only single-dose formulations of annual influenza vaccines that are free of thimerosal ● July 2025: these recommendations were adopted by the HHS Secretary and are now official recommendations of the CDC. Source: CDPH Provider Office Hours Fewer Infants Hospitalized for RSV in 2024-2025 after Prenatal and Infant RSV Immunizations Introduced ● Prenatal and infant RSV immunizations were introduced in 2023 – 2024. ● Infant RSV hospitalizations were lower in 2024 – 2025 RSV season compared to 2018–2020 in two national surveillance systems: RSVNET* and NVSN**. ○ Age 0-7 months: hospitalization rate reduced by 43% (RSV-NET); 28% (NVSN) ● Largest hospitalization rate reduction among infants 0-2 months ○ Age 0-2 months: hospitalization rate reduced by 52% (RSV-NET); 45% (NVSN) *RSV-NET: RSV-Associated Hospitalization Surveillance Network in 300 hospitals across 13 states **NVSN: New Vaccine Surveillance Network in 7 U.S. medical centers Source: CDPH Provider Office Hours |
CDC Adopts Recommendation for Clerovimab
- ACIP recommended infants aged < 8 months born during or entering their first RSV season who are not protected by maternal vaccination receive one dose of clesrovimab.
- There is no preferential recommendation between nirsevimab and clesrovimab.
- This recommendation was adopted by the CDC Director on August 4, 2025, and is now an official recommendation of the CDC.
Source: CDPH Provider Office Hours
WHERE TO GET VACCINATED:

Visit ICLAC’s Where to Get Vaccinated page to learn which routine and recommended vaccines are needed for you or a family member, how to find a vaccination clinic near you, or how to request in-home vaccination. Information provided is for all routine and recommended vaccines throughout the lifespan, including COVID-19 and flu.

Visit the Administration for Strategic Preparedness & Response (ASPR) COVID-19 and Flu Treatments Locator page to find nearby pharmacies, clinics, and other locations with COVID-19 and flu medications. Please note that these medications require a prescription from a healthcare provider.

Visit VaxAssist’s Respiratory Vaccination Locator to check eligibility and find and schedule vaccinations. Available in English and Spanish.
WEBINARS, TOWNHALLS, TRAININGS, AND EVENTS

Webinar: CDPH Immunization Branch Provider Webinars
The CDPH Immunization Updates for Providers webinar series has changed as of July 2025:
- New Name: CDPH Immunization Updates for Providers Monthly Webinar
- New Cadence: 1 session per month for the remainder of 2025 (9:00-10:30am PT)
- September 19
- October 24
- November 21
- December 19
Webinar: Current Issues in Vaccines – Aluminum Adjuvants: Separating Fact from Fear
Join the Vaccine Education Center (VEC) at Children’s Hospital of Philadelphia’s upcoming “Current Issues in Vaccines” webinar at 9:00 – 10:00 AM PT on September 10, 2025. Dr. Offit will be discussing “Aluminum Adjuvants: Separating Fact from Fear.” Continuing education credits will be offered. CME and CEU will be processed through the University of Pittsburgh, and CPE will be processed through Wilkes University. Questions submitted during the event will be addressed and posted online within a week of the event. Slides will also be posted along with a link to the archived event. VEC would like to acknowledge the ongoing support from the Thomas F. McNair Scott Endowed Research and Lectureship Fund, which enables them to offer this program, and they would like to thank our co-sponsors, the Pennsylvania chapter of the American Academy of Pediatrics and the Nesbitt School of Pharmacy at Wilkes University.
Webinar: AMGA Rise to Immunize – Improving Preventive Care: Strengthening Hepatitis B Vaccine Delivery in Clinical Practice
Join the American Medical Group Association’s monthly Rise to Immunize webinar on September 18th from 11:00 AM – 12:00 PM PT. Nkem Akinsoto, MSc, and Jerrome Sicat, RN (UW Medicine Primary Care and Population Health) will discuss Strengthening Hepatitis B Vaccine Delivery in Clinical Practice.


